Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

SciSparc Ltd. (SPRC)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.9380-0.0020 (-0.21%)
At close: 04:00PM EDT
0.9250 -0.01 (-1.39%)
After hours: 07:59PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.9400
Open0.9600
Bid0.9300 x 1000
Ask0.9250 x 800
Day's Range0.8800 - 1.0700
52 Week Range
Volume4,077,255
Avg. Volume999,373
Market Cap2.157M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-3.4230
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    SciSparc Signs a Non- Binding Letter of Intent to Acquire American Food Supplements and Cosmetics Brand in Approximately $20 Million Deal

    The Letter of Intent contemplates the purchasing of a brand, trademark and Amazon.com seller account, a management agreement, a U.S. distribution agreement and an option to expand to new territories TEL AVIV, Israel, Aug. 15, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced that it has signed a non-binding let

  • GlobeNewswire

    SciSparc Issued Israeli Patent for its Core Technology for Treating Central Nervous Systems Disorders

    Patent extends protection for SciSparc’s novel compounds and methods already granted in the U.S., Australia and Japan TEL AVIV, Israel, Aug. 12, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ: SPRC), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system (the “Company” or “SciSparc”), today announced it has been granted an Israeli patent for its core technology that treats central nervous systems disorders. The

  • GlobeNewswire

    SciSparc Announces Israeli Ministry of Health Approval to Conduct its Clinical Trial in Autism Spectrum Disorder

    The trial's objectives are to evaluate the safety, tolerability and efficacy of SciSparc's SCI-210 in children and adolescents with ASD TEL AVIV, Israel, Aug. 08, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced that it has received approval from the Israeli Ministry of Health to conduct the Company’s clinical

Advertisement
Advertisement